Tomoaki Shirakawa
- kawaokashinpei3
- 5月20日
- 読了時間: 2分
Selected journal : Cell Metabolism
Mitochondrial transfer from immune to tumor cells enables lymph node metastasis
What is the main question of the paper?
Why can tumor cells metastasize to and colonize lymph nodes, despite the fact that lymph nodes are rich in immune cells and would therefore seem to be an unfavorable environment for tumor cell engraftment?
How did the anthor address the question?
■Step1
1. They showed that tumor cells acquire mitochondria from immune cells involved in anti-tumor immunity. First, using multiple mouse tumor models, including MC38 colorectal cancer, E0771 breast cancer, and B16 melanoma, the authors demonstrated in vivo that tumor cells acquire mitochondria derived from surrounding immune cells.
■Step2
2. They showed that immune cells that lose mitochondria have impaired anti-tumor immune functions. On the immune cell side, they showed that the expression of antigen-presentation machinery and co-stimulatory molecules was reduced. They also demonstrated that the activation and cytotoxic activity of NK cells and CD8 T cells were impaired. In other words, tumor cells weaken anti-tumor immune responses by acquiring mitochondria from immune cells.
■Step3
3. They showed that tumor cells receiving mitochondria activate the cGAS–STING/type I interferon pathway, thereby promoting lymph node metastasis. On the tumor cell side, the acquired mitochondria fuse with the mitochondrial network inside tumor cells, and leaked mitochondrial DNA activates the cGAS–STING pathway. cGAS–STING is an innate immune pathway that detects cytosolic DNA. In this study, the authors position the downstream type I interferon response as an immune-evasion program in tumor cells that promotes lymph node metastasis. They also showed that inhibition of this pathway reduces lymph node metastasis, supporting mitochondrial transfer as a causal mechanism that promotes lymph node metastasis.
What is the “strength” of the paper?
The strength of this study is that it focuses on a single phenomenon, mitochondrial transfer, and explains it from two directions: functional impairment of the donor immune cells and acquisition of metastatic ability by the recipient tumor cells. This structure effectively connects mitochondrial transfer to the ability of tumor cells to metastasize to and colonize lymph nodes. In particular, the study interestingly reframes the immune-cell-rich lymph node environment not as a “barrier” for tumor cells, but rather as a “resource” that tumor cells can exploit.
Comment
This study demonstrates, step by step, that mitochondrial transfer—a form of interaction between tumor cells and immune cells—suppresses antitumor immunity and promotes lymph node metastasis. Finally, analysis of a dataset from human cancer patients confirmed that mitochondrial gene expression is elevated in metastatic lymph nodes and strongly correlates with cGAS/SING activation, suggesting potential for clinical application in the prevention of lymph node metastasis
Comment by Yuki Nakamura
